Thomas J Povsic, Timothy D Henry, Jay H Traverse, R David Anderson, Geoffrey A Answini, Benjamin C Sun, George J Arnaoutakis, Konstantinos D Boudoulas, Adam R Williams, Howard C Dittrich, Elizabeth A Tarka, David A Latter, E Magnus Ohman, Mark W Peterson, Dawn Byrnes, Carl J Pepine, Marcelo F DiCarli, Ronald G Crystal, Todd K Rosengart, Nahush A Mokadam
BACKGROUND: New therapies are needed for patients with refractory angina. Encoberminogene rezmadenovec (XC001), a novel adenoviral-5 vector coding for all 3 major isoforms of VEGF (vascular endothelial growth factor), demonstrated enhanced local angiogenesis in preclinical models; however, the maximal tolerated dose and safety of direct epicardial administration remain unknown. METHODS: In the phase 1 portion of this multicenter, open-label, single-arm, dose-escalation study, patients with refractory angina received increasing doses of encoberminogene rezmadenovec (1×109 , 1×1010 , 4×1010 , and 1×1011 viral particles) to evaluate its safety, tolerability, and preliminary efficacy...
July 28, 2023: Circulation. Cardiovascular Interventions